Stefano Barco
Stefano Barco is an expert in Cardiology at University Hospital of Zurich (Switzerland). As of August 2026, ScienceLeadR ranks Stefano Barco in the top 1% of experts worldwide for Pulmonary Embolism, Embolism and Thrombosis and Coronavirus Infections. Stefano Barco has authored 392 publications, the most recent in 2026, and is an investigator in 18 clinical trials, 4 of them ongoing. SLR score: 1,778 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Hematology - Public Health - Pulmonology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2006 - 2026
Number : 392
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Lower extremity amputations in Switzerland: Trends in patients with and without diabetes, 2013-2023. PMID 42656925 — diabetes mellitus, mortality, hospital mortality, amputation, surgical | Int J Cardiol Cardiovasc Risk Prev | 2026 | 0 |
| Ruling out acute pulmonary embolism with SPECT V/Q: comment on the primary results of the SPECTACULAR non-inferiority trial. PMID 42492989 — embolism, respiration, tomography, emission-computed, single-photon, pulmonary embolism | Eur Respir J | 2026 | 0 |
| Outcomes in venous thromboembolism with retained vs removed inferior vena cava filters: an analysis from the Registro Informatizado de Enfermedad TromboEmbólica. PMID 42436733 — registries, anticoagulants, mortality, vena cava filters, thromboembolism, hemorrhage, incidence, vena cava, inferior, venous thromboembolism | Res Pract Thromb Haemost | 2026 | 0 |
| Association of Obesity With Mortality and Bleeding in Cancer-Associated Venous Thromboembolism. PMID 42341875 — registries, mortality, thromboembolism, embolism, hemorrhage, neoplasms, obesity, venous thromboembolism | Mayo Clin Proc | 2026 | 0 |
| Early discharge and home treatment after acute pulmonary embolism. PMID 42316855 — embolism, angiography, vascular diseases, pulmonary embolism, therapeutics, outpatients | Vasa | 2026 | 0 |
Clinical Studies 18
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 3
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty NCT06611319 — arthroplasty, anticoagulants, thromboembolism, embolism, rivaroxaban, recycling, tablets, pulmonary embolism, enhanced recovery after surgery, venous thromboembolism, thrombosis, veins, direct-acting oral anticoagulants | Phase 3 | Recruiting | 2024 |
| Ultrasound facilitated Catheter directed Thrombolysis in Intermediate high Risk Pulmonary Embolism NCT04790370 — embolism, blood, fibrinolysis, heparin, pulmonary embolism, therapeutics, heparin, low-molecular-weight, random allocation, catheters | Phase 4 | Active not recruiting | 2021 |
| Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk NCT04774159 — mortality, stroke, myocardial infarction, colchicine, pharmaceutical preparations, tablets, arteries, atherosclerosis, peripheral arterial disease, therapeutics, ischemia | Phase 3 | Recruiting | 2021 |
| Pulmonary Embolism International THrOmbolysis Study 3 NCT04430569 — embolism, plasminogen, plasminogen activators, tissue plasminogen activator, pulmonary embolism, therapeutics, tissues, infusions, intravenous | Phase 3 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map